Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 5, 2013, Pages 549-556

  Langenhuijsen, Johan F ^a   Badhauser, Dirk ^b   Schaaf, Berthold ^c   Kiemeney, Lambertus A L M ^a   Witjes, J Alfred ^a   Mulders, Peter F A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sanofi   (Germany)

^c Offenbach/Main ^*  (Germany)

Author keywords

Intermittent androgen deprivation; Prostate cancer; Prostate specific antigen; Testosterone

Indexed keywords

BUSERELIN; NILUTAMIDE; TESTOSTERONE;

ADULT; AGED; ALCOHOL INTOLERANCE; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PAIN; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION; CONSTIPATION; CONTINUOUS ANDROGEN DEPRIVATION THERAPY; CONTROLLED STUDY; DATA ANALYSIS; DEPRESSION; DYSPNEA; ERECTILE DYSFUNCTION; GYNECOMASTIA; HOT FLUSH; HUMAN; INTERMETHOD COMPARISON; INTERMITTENT ANDROGEN DEPRIVATION THERAPY; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; VISUAL DISORDER;

AGED; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NAUSEA; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; VISION DISORDERS;

EID: 84879464358     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.03.008     Document Type: Article

References (23)

1. Denis L., Murphy G.P. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer 1993, 72(Suppl):3888-3895.
2. Thompson C.A., Shanafelt T.D., Loprinzi C.L. Andropause: Symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003, 8:474-487.
3. Higano C.S. Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity. Urology 2003, 61(2 Suppl 1):32-38.
4. Braga-Basaria M., Dobs A.S., Muller D.C., et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979-3983.
5. Akakura K., Bruchovsky N., Rennie P.S., et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol 1996, 59:501-511.
6. Sato N., Gleave M.E., Bruchovsky N., et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 1996, 58:139-146.
7. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995, 45:839-845.
8. Gleave M., Bruchovsky N., Goldenberg S.L., et al. Intermittent androgen suppression for prostate cancer: Rationale and clinical experience. Eur Urol 1998, 34(3):37-41.
9. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006, 24:3984-3990.
10. Kurth K. The application of response criteria on reporting treatment results in cancer trials. Prog Clin Biol Res 1990, 359:49-64.
11. Prapotnich D., Fizazi K., Escudier B., et al. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003, 43:233-240.
12. Salonen A.J., Viitanen J., Lundstedt S., et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: Interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol 2008, 180:915-920.
13. Grossfeld G.D., Small E.J., Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer: Initial experience. Urology 1998, 51:137-144.
14. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 2005, 173:1567-1571.
15. Tunn U.W., Kurek R., Kienle E., et al. Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy. J Urol 2004, 171. [Abstract 1459].
16. Pettersson B., Varenhorst E., Petas A., et al. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localized carcinoma of the prostate. A 12-month follow-up study. Eur Urol 2006, 50:483-489.
17. de Leval J., Boca P., Yousef E., et al. Intermittent vs. continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002, 1:163-171.
18. Calais da Silva F.E., Bono A.V., Whelan P., et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomized phase 3 study of the South European Uro-oncological Group. Eur Urol 2009, 55:1269-1277.
19. de Conti P., Atallah A.N., Arruda H.O., et al. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007, CD005009.
20. Spry N.A., Kristjanson L., Hooton B., et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006, 42:1083-1092.
21. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J Clin Oncol 1999, 17:3461-3467.
22. Colette L., Burzykowski T., Schroeder F.H. Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer 2006, 42:1344-1350.
23. Shaw G.L., Wilson P., Cuzick J., et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: A meta-analysis of 1446 patients. BJU Int 2007, 99:1056-1065.